Experimental brain cancer therapy targets tumors directly

NCT ID NCT07386002

Not yet recruiting Disease control Sponsor: T-MAXIMUM Pharmaceutical Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called MT027 for people with recurrent glioblastoma, an aggressive brain cancer. MT027 uses specially engineered immune cells (UCAR-T cells) that are injected directly into the fluid around the brain. The trial will include 40 adults aged 18-70 and aims to check safety and whether it helps patients live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MT027 UCAR-T cells (a type of immune cell therapy) targeting B7H3
What this could lead to: If successful, this could offer a new treatment option for people with recurrent glioblastoma, potentially extending survival.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The treatment involves direct brain injection and carries risks like brain swelling or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IDH-wildtype glioblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE

Contacts and locations

Locations

Chang Gung Memorial Hospital, Kaohsiung

Kaohsiung City, 833401, Taiwan
Chang Gung Memorial Hospital, Linkou

Taoyuan, 333423, Taiwan
Hualien Tzu Chi Hospital

Hualien City, 970473, Taiwan
The Johns Hopkins Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.